Nesina

533 views
275 views

Published on

Nesina,Nesina, drug, newerdrug, newdrug, FDA, Pharmacy, pharmd, vels, therapeutics, algoliptin

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
533
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
7
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Nesina

  1. 1. DRUG FOR THE WEEK NESINA
  2. 2. NESINA •Therapeutic class:-Dipeptidyl peptidase 4-inhibitor •Generic name:-Alogliptin benzoate •Trade name:-Nesina •FDA Approved date :- 26 January 2013
  3. 3. •Company name:- Takeda •Cost:- 25 mg (Rs.209.40) ,12.5 mg(Rs.112.20), 6.25mg (Rs.60.40) • •Indications:- Type 2 diabetes mellitus •Dosage:- • Adults:- Usual- 25mg- qd • Renal Impairment: Moderate : 12.5mg qd •. End-Stage Renal Disease/severe: 6.25mg qd. •Pregnancy:- •Category B
  4. 4. •Mechanism of action:- It increases the activation of incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting postprandial glucose concentrations . •Pharmacokinetics:- Absorption:- Absolute bioavailability (100%) Distribution:- 20% plasma protein binding Metabolism:- hepatic metabolism occurs Elimination:- Feces (13%), Urine (76%), T1/2=21 hrs
  5. 5. •Adverse drug reactions:- • Hypoglycemia • Nasopharyngitis •Throbbing headache •Drug interactions:- • Bexarotene • Gatifloxacin
  6. 6. •Warning and Precautions:- •Not for use in type 1 diabetes, diabetes ketoacidosis •D/c if pancreatitis is suspected •Use with caution in patients with abnormal LFTs Patient counselling:- •Avoid alcohol consumption •If a dose is missed not to take a double dose •Inform signs / symptoms of pancreatitis •Instruct to inform physician if unusual symptom develops or if a symptom persists/worsens.

×